Miaozhu

Postdoctoral Associate in Genetic Epidemiology. Happiness is about having each tiny wish come true.

[Miaozhu @Selaginellav]

Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants https://t.co/pIgg1oXibO

[Miaozhu @Selaginellav]

The AI Impact with Generate: Biomedicines' Mike Nally https://t.co/vhltpA5nlp

[Miaozhu @Selaginellav]

2024 CEO Chat: Mike Nally, CEO of Generate:Biomedicines https://t.co/5rlWuaF20N via @YouTube six months dosing is realistic, anti-TSLP molecule

[Miaozhu @Selaginellav]

structure - function, CryoEM

[Kiniksa Pharmaceuticals @kiniksa]

Check out @HLundqvist on the #TODAYshow to learn more about the Life DisRPted campaign.

[Eric Topol @EricTopol]

A prospective, multicenter study of label-free #AI classification of brain tumors (diffuse gliomas) with 93% accuracy in <90 seconds
https://t.co/YAt0QZDB2y @NatureMedicine @ToddCHollon @umichneuro @mlins_lab #DeepGlioma

[Eric Topol @EricTopol]

🆕 Our review of #AI for medicine, just published @NatureMedicine
https://t.co/OAoAGmErns
@pranavrajpurkar, Emma Chen, Oishi Banerjee

[Miaozhu @Selaginellav]

@pansareV @bradloncar You know what, I bought LABU, Direxion Daily S&P Biotech Bull 3X Shares ARCX, in two weeks it went down almost 40%😢😔

[Brad Loncar @bradloncar]

Individual biotechs are trading crazy lately. A $3B company I follow trades down 10%+ during the first 15 min on semi-light volume and now makes it back to green. Clearly a fund blowing out of the position in the morning (there was no meaningful news). This is a $3B co not $30M.

[Brad Loncar @bradloncar]

Is there a worse thing an analyst can say about a biotech company than "2022 is about execution." In other words, no data on the horizon, see you in 2023.

[Ned Pagliarulo @NedPagliarulo]

Pfizer, a company with half a dozen $1B+ drugs, is dedicating its entire JPM presentation to mRNA and the 3 deals (Beam, Acuitas, Codex) it's announced today. That's telling.

https://t.co/zyBABaOrEc

[Brad Loncar @bradloncar]

The #JPM22 schedule is up.

[Brad Loncar @bradloncar]

I wrote about some of the structural things (i.e. not data) that have held biotech back this year. $XBI https://t.co/ytPgnUg5gO

[Eric Topol @EricTopol]

In case you needed more evidence or real-world effectiveness of the mRNA vaccines, the new @CDCMMWR report shows 93.5% protection vs symptomatic infections among health care workers (nice that it = clinical trials)
https://t.co/yVO60eIxJ3

[Miaozhu @Selaginellav]

@camelus_minimus Hi Jan, I am Miaozhu. Do you still remember me?I studied epidemiology in your mom Prof. Krämer's lab.I really thank for her support and care. How are you&your parents? It seems virus is serious in Germany, I try to contact her via email, but not sure she got it. Wish you all well

[Miaozhu @Selaginellav]

The opportunities that were important…that were gonna come to me…were few and the trick was to prepare myself for seizing the few that came. You’re going to blow one occasionally. My general idea is there’s no point in fretting too much about what you can’t fix.

[Miaozhu @Selaginellav]

https://t.co/JxP3wstPOj Charlie Munger Speaks at Daily Journal Annual Meeting -- Feb. 14, 2019

[Miaozhu @Selaginellav]

Over a 50% increase!!!

[Bruce Booth @LifeSciVC]

Number of publicly traded biotech stocks is up 50% in a few years: The Incredible Expanding Universe of Biotech Stocks. ICYMI. https://t.co/3dwum3x26B

[Jonathan Aufray @jonathan_aufray]

Top 10 disruptive #technology trends: #AI enablement, smart #logistics, #IoT software, connected #health... Via @CorumGroup

[Miaozhu @Selaginellav]

Check safe zone

[Eric Topol @EricTopol]

From @kaifulee's super book #AISuperpowers, projections of "risk of replacement" for cognitive and physical labor. As he puts the bottom line:
"Within 10-20 years, I estimate we will be technically capable of automating 40-50% of jobs in the US"